Ipamorelin: Ipamorelin (Growth Hormone Secretagogue)
Category: Growth & Performance
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is a pentapeptide (five amino acids) that was designed to be highly specific in its action. Unlike older growth hormone releasing peptides (GHRPs), ipamorelin does not significantly increase cortisol, prolactin, or ACTH levels, making it the cleanest GH secretagogue in its class.
This guide compiles key literature themes, handling context, and practical comparison points for research-focused evaluation.
Overview
This selectivity has made ipamorelin one of the most studied GH-releasing peptides in both preclinical and clinical settings. Researchers value its predictable dose-response relationship and minimal off-target effects.
Discovery & Background
Ipamorelin was developed by Novo Nordisk in the late 1990s through structure-activity relationship studies aimed at creating more selective GH secretagogues. Published research by Raun et al. (1998) established its selectivity profile. While Novo Nordisk ultimately did not commercialize it as a therapeutic, the compound became widely used in research due to its favorable selectivity characteristics.
Mechanism of Action
Ipamorelin works by binding to the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells, triggering a calcium-dependent release of growth hormone. Its selectivity comes from its unique binding profile.
- 1Binds selectively to the GHS-R1a (ghrelin) receptor on pituitary somatotroph cells
- 2Triggers growth hormone release through a calcium-dependent signaling cascade
- 3Does not significantly stimulate ACTH or cortisol release (unlike GHRP-6 and GHRP-2)
- 4Produces minimal increase in prolactin levels compared to other GH secretagogues
- 5Maintains the natural pulsatile pattern of GH release rather than creating constant elevation
- 6Dose-response is linear and predictable up to a saturation point
Research Benefits
The benefit areas below reflect commonly discussed research interests for this peptide.
Selective GH Release
Stimulates growth hormone release without elevating cortisol, prolactin, or ACTH, the cleanest profile of any GHRP.
Predictable Dosing
Linear dose-response curve makes it straightforward for researchers to design accurate protocols.
Body Composition
Animal studies show improvements in lean mass and reductions in fat mass with sustained administration.
Bone Density
Research demonstrates increased bone mineral density and improved bone turnover markers.
Published Research
Selectivity Profile
Ipamorelin released GH with potency and efficacy comparable to GHRP-6 but without affecting ACTH, cortisol, prolactin, or FSH levels.
Endocrinology, 1998
Bone Density
Chronic ipamorelin treatment increased bone mineral content and bone formation markers in adult female rats.
Bone, 2000
Dose-Response
GH release showed a clear dose-dependent relationship with ipamorelin, reaching maximum effect at approximately 1 mcg/kg.
European Journal of Endocrinology, 1999
Safety Profile
No significant adverse effects observed in animal studies at doses up to 10x the effective GH-releasing dose.
Growth Hormone & IGF Research, 2001
Reported Side Effects & Considerations
- •Headache and flushing reported at higher doses in early clinical work
- •Transient hunger increase possible due to ghrelin receptor activation
- •Water retention at higher doses (related to GH elevation)
- •No significant cortisol or prolactin elevation at standard research doses
Storage Guidelines
Temperature
-20C for long-term, 2-8C for short-term
Once Reconstituted
Use within 21 days when stored at 2-8C
Shelf Life
24 months lyophilized at -20C
Frequently Asked Questions
What makes ipamorelin different from other GH secretagogues?
Ipamorelin is the most selective GHRP available. It stimulates GH release without elevating cortisol, prolactin, or ACTH levels, which is unique among growth hormone releasing peptides.
How does ipamorelin compare to GHRP-6?
Both release similar amounts of GH, but GHRP-6 also increases cortisol, ACTH, and prolactin. GHRP-6 also causes significant hunger through stronger ghrelin receptor activation. Ipamorelin avoids these off-target effects.
Can ipamorelin be combined with other peptides?
Researchers commonly study ipamorelin in combination with CJC-1295, a GHRH analog. The two work through complementary pathways and together produce a greater GH response than either alone.
What is the typical research dosing?
Published studies typically use doses of 1 mcg/kg body weight for animal studies. The GH response is dose-dependent up to approximately this level before plateauing.
Does ipamorelin affect natural GH production?
Research suggests ipamorelin works with the body's natural feedback mechanisms rather than overriding them. It amplifies the natural GH pulse rather than creating constant elevation.
Research Disclaimer
This guide is for educational and informational purposes only. All information is based on published scientific research and peer-reviewed literature. Peptides sold by Peptrolix are intended solely for laboratory research use and are not for human consumption. Consult healthcare professionals before making any health decisions.
Shop Ipamorelin
99%+ purity, lab-tested with certificate of analysis.
Review variant options and quantity pricing before adding to cart.
View IpamorelinBrowse All PeptidesRelated Peptide Guides
Related searches:
- ipamorelin
- ipamorelin peptide
- growth hormone secretagogue
- ipamorelin research
- ipamorelin benefits
- ipamorelin vs sermorelin
- ipamorelin mechanism
- ghrp ipamorelin
Explore More Peptide Guides
Explore adjacent compounds to compare mechanisms, side-effect discussions, and study focus across related peptides.
Start Your Research Today
All peptides 99%+ purity with certificates of analysis.
Products from Peptrolix are supplied strictly for laboratory and scientific research use only.
Shop Peptides